Paper34831014
IGF1R/IR Mediates Resistance to BRAF and MEK Inhibitors in BRAF-Mutant Melanoma.
Patel H and 5 others. Cancers (Basel), 2021. Cited by 27 papers, by iCite.
Cite this record
ConductScience Library. IGF1R/IR Mediates Resistance to BRAF and MEK Inhibitors in BRAF-Mutant Melanoma. Papers, record 34831014. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/34831014
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| W81XWH1910441 | United States Department of Defense | PubMed |
Source PubMed
References63
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 31936151 | Dissecting Mechanisms of Melanoma Resistance to BRAF and MEK Inhibitors Revealed Genetic and Non-Genetic Patient- and Drug-Specific Alterations and Remarkable Phenotypic Plasticity. | Cells | 2020 | https://conductscience.org/library/papers/31936151 | PubMed |
| 2 | 23166326 | Biochemical characterization of individual human glycosylated pro-insulin-like growth factor (IGF)-II and big-IGF-II isoforms associated with cancer. | J Biol Chem | 2013 | https://conductscience.org/library/papers/23166326 | PubMed |
| 3 | 32150843 | A Possible Link of Genetic Variations in ER/IGF1R Pathway and Risk of Melanoma. | Int J Mol Sci | 2020 | https://conductscience.org/library/papers/32150843 | PubMed |
| 4 | 19996272 | BMS-754807, a small molecule inhibitor of insulin-like growth factor-1R/IR. | Mol Cancer Ther | 2009 | https://conductscience.org/library/papers/19996272 | PubMed |
| 5 | 30770389 | Targeting Alterations in the RAF-MEK Pathway. | Cancer Discov | 2019 | https://conductscience.org/library/papers/30770389 | PubMed |
| 6 | 30404005 | BRAF Splice Variant Resistance to RAF Inhibitor Requires Enhanced MEK Association. | Cell Rep | 2018 | https://conductscience.org/library/papers/30404005 | PubMed |
| 7 | 10229198 | Insulin receptor activation by IGF-II in breast cancers: evidence for a new autocrine/paracrine mechanism. | Oncogene | 1999 | https://conductscience.org/library/papers/10229198 | PubMed |
| 8 | 32843616 | IGF-1R inhibition induces MEK phosphorylation to promote survival in colon carcinomas. | Signal Transduct Target Ther | 2020 | https://conductscience.org/library/papers/32843616 | PubMed |
| 9 | 31166680 | Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma. | N Engl J Med | 2019 | https://conductscience.org/library/papers/31166680 | PubMed |
| 10 | 18300768 | The MAPK pathway in melanoma. | Curr Opin Oncol | 2008 | https://conductscience.org/library/papers/18300768 | PubMed |
| 11 | 21521745 | Phosphoproteomic screen identifies potential therapeutic targets in melanoma. | Mol Cancer Res | 2011 | https://conductscience.org/library/papers/21521745 | PubMed |
| 12 | 19029956 | Insulin and insulin-like growth factor signalling in neoplasia. | Nat Rev Cancer | 2008 | https://conductscience.org/library/papers/19029956 | PubMed |
| 13 | 17473213 | Implication of the insulin-like growth factor-IR pathway in the resistance of non-small cell lung cancer cells to treatment with gefitinib. | Clin Cancer Res | 2007 | https://conductscience.org/library/papers/17473213 | PubMed |
| 14 | 30833419 | Resistance to MAPK Inhibitors in Melanoma Involves Activation of the IGF1R-MEK5-Erk5 Pathway. | Cancer Res | 2019 | https://conductscience.org/library/papers/30833419 | PubMed |
| 15 | 21217522 | Insulin-like growth factor receptor-1 (IGF-1R) expression in normal breast, proliferative breast lesions, and breast carcinoma. | Appl Immunohistochem Mol Morphol | 2011 | https://conductscience.org/library/papers/21217522 | PubMed |
| 16 | 30841853 | iGEAK: an interactive gene expression analysis kit for seamless workflow using the R/shiny platform. | BMC Genomics | 2019 | https://conductscience.org/library/papers/30841853 | PubMed |
| 17 | 29019177 | Long-Term Survival after Complete Surgical Resection and Adjuvant Immunotherapy for Distant Melanoma Metastases. | Ann Surg Oncol | 2017 | https://conductscience.org/library/papers/29019177 | PubMed |
| 18 | 28923912 | Exploiting Drug Addiction Mechanisms to Select against MAPKi-Resistant Melanoma. | Cancer Discov | 2018 | https://conductscience.org/library/papers/28923912 | PubMed |
| 19 | 25452114 | Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma. | Nat Commun | 2014 | https://conductscience.org/library/papers/25452114 | PubMed |
| 20 | 21654344 | Comprehensive analysis of receptor tyrosine kinase activation in human melanomas reveals autocrine signaling through IGF-1R. | Melanoma Res | 2011 | https://conductscience.org/library/papers/21654344 | PubMed |
Cited by19
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 27 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42196460 | Dynamic Time-Resolved Remodeling of the Immune Microenvironment After Resistance to BRAF/MEK Inhibitors in Melanoma: Mechanisms, Biomarkers, and Emerging Therapeutic Strategies. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42196460 | PubMed |
| 42182948 | Association of serum vitamin D and serum vitamin C with the risk of melanoma among adults in the United States: a cross-sectional analysis of 2003-2006 and 2017-2018 NHANES data. | J Clin Biochem Nutr | 2026 | https://conductscience.org/library/papers/42182948 | PubMed |
| 41807883 | BRAF inhibitor resistance in melanoma: from resistance mechanisms to therapeutic innovations. | Mol Biomed | 2026 | https://conductscience.org/library/papers/41807883 | PubMed |
| 40527402 | IGF-1R inhibitors in cancer: A review of available evidence and future outlook. | Crit Rev Oncol Hematol | 2025 | https://conductscience.org/library/papers/40527402 | PubMed |
| 40515636 | Anoikis classification of lung squamous cell carcinoma reveals correlation with clinical prognosis and immune characteristics. | Ann Med | 2025 | https://conductscience.org/library/papers/40515636 | PubMed |
| 40092985 | Inhibiting melanoma tumor growth: the role of oxidative stress-associated LINC02132 and COPDA1 long non-coding RNAs. | Front Immunol | 2025 | https://conductscience.org/library/papers/40092985 | PubMed |
| 40071065 | Targeting Surface Markers in Anaplastic Thyroid Cancer: Future Directions in Ligand-bound Therapy. | J Endocr Soc | 2025 | https://conductscience.org/library/papers/40071065 | PubMed |
| 38691253 | Pan-cancer analysis of prognostic and immunological role of IL4I1 in human tumors: a bulk omics research and single cell sequencing validation. | Discov Oncol | 2024 | https://conductscience.org/library/papers/38691253 | PubMed |
| 38278874 | BRAF - a tumour-agnostic drug target with lineage-specific dependencies. | Nat Rev Clin Oncol | 2024 | https://conductscience.org/library/papers/38278874 | PubMed |
| 37834284 | Tumor Cell Resistance to the Inhibition of BRAF and MEK1/2. | Int J Mol Sci | 2023 | https://conductscience.org/library/papers/37834284 | PubMed |
| 37465678 | Comprehensive bioinformatics analysis reveals the crosstalk genes and immune relationship between the systemic lupus erythematosus and venous thromboembolism. | Front Immunol | 2023 | https://conductscience.org/library/papers/37465678 | PubMed |
| 37175614 | Trametinib-Resistant Melanoma Cells Displaying MITFhigh/NGFRlow/IL-8low Phenotype Are Highly Responsive to Alternating Periods of Drug Withdrawal and Drug Rechallenge. | Int J Mol Sci | 2023 | https://conductscience.org/library/papers/37175614 | PubMed |
| 36829149 | Efficient prioritization of CRISPR screen hits by accounting for targeting efficiency of guide RNA. | BMC Biol | 2023 | https://conductscience.org/library/papers/36829149 | PubMed |
| 36497341 | Epigenetic Mechanisms Underlying Melanoma Resistance to Immune and Targeted Therapies. | Cancers (Basel) | 2022 | https://conductscience.org/library/papers/36497341 | PubMed |
| 35968344 | Nuclear interaction of Arp2/3 complex and BRAFV600E promotes aggressive behavior and vemurafenib resistance of thyroid cancer. | Am J Cancer Res | 2022 | https://conductscience.org/library/papers/35968344 | PubMed |
| 35912223 | The Evolution of BRAF Activation in Non-Small-Cell Lung Cancer. | Front Oncol | 2022 | https://conductscience.org/library/papers/35912223 | PubMed |
| 35565444 | Potential Biomarkers of Skin Melanoma Resistance to Targeted Therapy-Present State and Perspectives. | Cancers (Basel) | 2022 | https://conductscience.org/library/papers/35565444 | PubMed |
| 35513054 | The future of targeted kinase inhibitors in melanoma. | Pharmacol Ther | 2022 | https://conductscience.org/library/papers/35513054 | PubMed |
| 35410220 | Identification of IGF1R mutation as a novel predictor of efficacious immunotherapy in melanoma. | J Transl Med | 2022 | https://conductscience.org/library/papers/35410220 | PubMed |
Genes25
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/34831014
GET https://conductscience.org/api/papers/v1/34831014/references?page=2